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Transient myeloproliferative disorder (TMD) is a disorder almost exclusively reported in infants with Down syndrome (DS), with an incidence of approximately 4–10% [1,2]. It is 
characterized by increased numbers of circulating megakaryoblasts 
and multisystem involvement. Often, the clinical and 
morphological features may be indistinguishable from DS -related 
acute megakaryoblastic leukemia (DS-AMKL). The presence of 
either the former or the latter in an apparently normal newborn 
must prompt a detailed evaluation for an underlying syndrome, 
especially trisomy 21. TMD usually undergoes spontaneous 
remission in 2–3 months and does not require chemotherapeutic 
intervention; however, severe or life-threatening features may 
warrant chemotherapy [1]. About 20–30% of neonates with TMD 
develop DS-AMKL within 3–4 years of life and need regular 
follow-up and screening for the same [1,2].
CASE REPORT
A male neonate presented at 19 days of life with complaints of 
abdominal distension, umbilical discharge, high-grade fever, 
and refusal to feed. The neonate was born by a full-term vaginal 
delivery to a 26-year-old gravida-3, para-2, living-2 mother 
with an uneventful antenatal period. He was born of a non-
consanguineous marriage and his birth weight was 2590 g and birth 
order was third. Although no anomaly scan was done, two routine 
obstetric ultrasound scans in the third trimester were documented 
normal. The baby had an unremarkable postnatal course in the 
hospital and was discharged on exclusive breastfeeds. However, 
the mother reported intermittent feeding difficulty at home in the 
form of poor latching to the breast in the first 2 weeks of life.
On admission at our centre (Fig. 1), the neonate was lethargic, 
hemodynamically stable, with a patchy erythematous rash over 
the face and limbs, generalized abdominal distension with 
hepatosplenomegaly (liver 5 cm in the midclavicular line and 
spleen 3 cm along the splenic axis) and shifting dullness. Physical 
examination revealed no gross dysmorphic or syndromic features 
except for a suspected clinodactyly.
A provisional diagnosis of late-onset sepsis with suspected 
meningitis was made; a lumbar puncture was done which was 
normal. The hemogram report at admission showed a white blood 
cell (WBC) count of 72,800/mm3. The hemoglobin (Hb) was 
17.0 g/dL and platelet count was 242,000/mm3. Repeat hemograms 
on day 2 and 3 of admission showed persistently raised WBC 
count of 74,200/mm3 and 71,600/mm3, respectively. The liver 
function tests showed total bilirubin of 2.1 mg/dl with aspartate 
aminotransferase and alanine aminotransferase being 72 IU/L and 
52 IU/L, respectively, and lactate dehydrogenase was 1325 U/L.
The peripheral smear (Fig. 2) revealed 29% blasts with 
cytoplasmic blebs suggestive of megakaryoblasts. The bone 
marrow aspirate and biopsy samples were inadequate to diagnose 
acute leukemia. The peripheral blood flow cytometry revealed 
acute myeloid leukemia (CD33+, CD117+) with CD7, CD38, 
CD34, and HLA-DR expression but negative for CD3, CD19, and 
CD20. Cytogenetic study of the bone marrow aspirate revealed 
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no MLL gene translocation. The child was started on hydroxyurea 
(10 mg/kg/day) in view of the persistently high counts to prevent 
leukostasis and associated morbidity. Following this, the WBC 
count dropped to 36,100/mm3 within a few days.
In the setting of congenital acute leukemia, the mild dysmorphism 
in the baby was revisited. Hall’s criteria for the diagnosis of Down’s 
syndrome were applied but negative [3]. A peripheral blood karyotype 
detected trisomy 21 in all the 15 metaphases studied. In light of the 
above findings, a revised diagnosis of myeloid proliferation related 
to DS was made, with a high probability of TMD.
The neonate developed malena, hematochezia, and resultant 
anemia with congestive cardiac failure requiring a blood and 
fresh frozen plasma transfusions. The PT/INR was 17/1.3 and 
echocardiography showed a thin rim of pericardial effusion. Tumor 
lysis markers were monitored daily after starting hydroxyurea and 
appropriately managed. Gross ascites was documented on serial 
ultrasound scans, and significant weight loss ensued (Fig. 3) 
which was tackled by calorie-dense feeding.
In view of the stormy course that the baby was going through, 
unrelenting gross ascites and clinically significant bleeding, 
the chemotherapeutic intervention was started with cytarabine 
(1 mg/kg/day) given subcutaneously for 5 days. Following its 
administration, normalization of WBC counts (12,300/mm3), 
weight gain, and improvement in the clinical condition were seen 
over the next 2 weeks. A repeat flow cytometry and bone marrow 
study showed no evidence of blasts. However, the neonate 
developed anemia and leukopenia following chemotherapy which 
reached its nadir a week after administration (Hb=7.0 g/dL, WBC 
count=3700/mm3 with an absolute neutrophil count of 1147/mm3) 
and recovered in the following week. Subsequently, neonate 
developed Candida glabrata sepsis with osteomyelitis at multiple 
sites, which was managed with both antibacterial and antifungal 
agents for 6 weeks. The child was discharged after 4 months of 
intensive care with hemogram monitoring at 3 monthly intervals 
to screen for progression to DS-AMKL.
No congenital anomalies were discovered on echocardiography. 
Thyroid profiles done at birth and at 1 year of age were normal. 
Otoacoustic emission screening at birth and brainstem evoked 
response audiometry at 4 months of age revealed hearing sensitivities 
within normal limits bilaterally. The dysmorphic phenotype 
consistent with DS became more noticeable with advancing age. 
At 8, 10, 12, and 15 months of age, the child was hemodynamically 
stable on follow-up with no features of neoplastic progression. The 
hemogram done at 15 months revealed Hb of 11.6 g/dL, WBC count 
of 8800/mm3, and platelet count of 299,000/mm3. The child was 
developmentally delayed in the gross motor and speech domains 
when examined at both 8 and 15 months. At 15 months, he was able 
to stand with support and speak monosyllables. Milestones in the 
fine motor and social domains were appropriate for age.
DISCUSSION
Trisomy 21 or DS is the most common chromosomal abnormality 
in humans and confers a higher risk of developing leukemia in 
childhood. Occasionally, when the phenotypic features are subtle, 
as in our case, or in a mosaic; the occurrence of TMD may be the 
first indication that the child has trisomy 21. In this situation, the 
application of Hall’s criteria may aid in the diagnosis; however, 
the diagnostic gold standard remains karyotyping.
Flow cytometry may show assorted coexpression of stem cell 
markers (CD34 and CD117), myeloid markers (CD33/CD13), 
Figure 1: Neonate on admission, with gross abdominal distension, no 
dysmorphic features present
Figure 2: Peripheral smear reveals atypical cells with high 
nucleocytoplasmic ratio and scanty, gray-blue cytoplasm with blebs, 
suggestive of megakaryoblasts
Figure 3: Neonate on day of life 40 shows marked emaciation with 
dysmorphism becoming more apparent
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and megakaryocyte markers (CD36, CD41, CD42b, and CD61) 
together with CD56, CD7, and HLA-DR expression [2,4]. Flow 
cytometry revealed a predominance of myeloid series markers 
in the child; however, CD41 and CD61 were not done as TMD 
and DS were not suspected initially. The repeat flow cytometry 
done after cytarabine therapy revealed no blasts, and hence, 
immunohistochemistry could not be done. The diagnosis of TMD 
could not be confirmed by a GATA-1 mutation study due to 
financial limitations but was the most probable diagnosis in this 
clinical context.
Nearly 80% of TMD cases remit spontaneously; however, 
ominous features such as hydrops fetalis with gross ascites, 
extreme leukocytosis (WBC>100×106/dL), hepatopathy, diffuse 
intravascular coagulation (DIC) with bleeding, and renal and/or 
cardiac failure may increase mortality up to 20% [1]. Ascites, 
clinically significant bleeding and weight loss complicated the 
course of the child in the neonatal intensive care unit. Low-dose 
cytarabine may be considered in such life-threatening situations 
as its metabolism in children with trisomy 21, is decreased 
with a consequent increase in drug efficacy and incidence of 
myelosuppression [2].
The Berlin-Frankfurt-Münster group recommended treatment 
with cytarabine (0.5–1.5 mg/kg for 3–12 days) for high-risk 
neonates with TMD [5]. They reported similar survival in the 
treatment and non-treatment groups, suggesting that cytarabine 
may have been effective, considering that the treated neonates 
had more severe disease. A higher dose of 3.33 mg/kg/day 
used in the “Children Oncology Group Study A2791” revealed 
a poor survival rate of 51%, with 96% incidence of Grade 3/4 
myelosuppression following administration [6]. In another study 
by the pediatric oncology group (9481), three children received 
low-dose cytarabine (0.4–1.5 mg/kg every 12 h for 5 or 7 days) 
and all of them showed remission [7]. However, no data exist as 
to whether cytarabine offers any protection from progress to acute 
megakaryoblastic leukemia in these children in the future.
Incidence of DS-AMKL is estimated to be 500 times more 
than in children without DS. It occurs in 20–30% of TMD cases 
and manifests within the first 3 years of life, which is earlier 
as compared to AMKL in children without DS. Thus, after 
remission of TMD is documented, regular screening of clinical 
and hematological parameters (with a hemogram and peripheral 
smear) to detect its onset is essential.
CONCLUSION
A hematological picture suggestive of myeloid leukemia or 
TMD in a neonate without clear features of DS must be carefully 
evaluated to rule out underlying trisomy 21. Although most 
cases remit spontaneously, the presence of life-threatening 
complications such as CCF or DIC may warrant chemotherapy. 
Regular follow-up is required to screen the child for DS-AMKL as 
20–30% neonates with TMD develop AMKL in early childhood.
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